Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen
- Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences (NIRS), Chiba (Japan)
- National Hospital Organization Chiba-East Hospital, Chiba (Japan)
- Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan)
- Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba (Japan)
- National Hospital Organization Kasumigaura Medical Center, Tsutiura (Japan)
Purpose: A phase I/II study on carbon ion radiotherapy for Stage I non-small-cell lung cancer (NSCLC) was first conducted between 1994 and 1999 and determined the optimal dose. Second, a Phase II study using the optimal dose was performed. The purpose of the present study was to clarify the local control and 5-year survival rates. Methods and Materials: Between April 1999 and December 2000, 50 patients with 51 primary lesions were treated. Using a fixed dose of 72 GyE in nine fractions over 3 weeks, the primary tumors were irradiated with carbon ion beams alone. The average age of the patients was 74.5 years. Thirty-three (66%) of these were medically inoperable. Local control and survival were determined by using the Kaplan-Meier method and the data were statistically processed by using the log-rank test. Results: All patients were observed for a minimum of 5 years or until death with a median follow-up time of 59.2 months (range, 6.0-83.0 months). The local control rate for all patients was 94.7%. The patients' 5-year cause-specific survival rate was 75.7% (IA: 89.4; IB: 55.1), and overall survival 50.0% (IA: 55.2; IB: 42.9). No toxic reactions in the lung greater than Grade 3 were detected. Conclusions: Carbon ion radiotherapy, a new treatment modality with superior benefits in terms of quality of life and activity of daily living, has been proven as a valid alternative to surgery for Stage I NSCLC and to offer particular benefits, especially for elderly and inoperable patients.
- OSTI ID:
- 20944725
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 67, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2006.10.006; PII: S0360-3016(06)03243-3; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Baseline Pulmonary Function as a Predictor for Survival and Decline in Pulmonary Function Over Time in Patients Undergoing Stereotactic Body Radiotherapy for the Treatment of Stage I Non-Small-Cell Lung Cancer
Hypofractionated High-Dose Proton Beam Therapy for Stage I Non-Small-Cell Lung Cancer: Preliminary Results of A Phase I/II Clinical Study